AlaMab Therapeutics, Inc. licensing deals
June 27, 2017
A Patch article highlights licensing agreements from a collaboration between Dr. An’s Core and the laboratory of Dr. Jean Jiang at UT Health San Antonio. These agreements permit AlaMab Therapeutics Inc. to develop antibodies based on work from Drs. Jiang and An as therapies targeting spinal cord injuries and breast cancer. Having received $4.5 million upfront, UT Health could receive up to $114 million if the drugs are approved.